Job Title: Portfolio Lead - Venture Creation & Commercialisation (Accelerator)
About NATi
The Nucleic Acid Therapeutics Initiative (NATi), hosted by A*STAR, is Singapore's national platform dedicated to advancing RNA-based medicines and accelerating drug and vaccine development. NATi's mission is to establish Singapore as a globally recognised hub of excellence in nucleic acid therapeutics research, clinical translation and commercialisation.
The NATi Accelerator manages a portfolio of more than 20 programmes originating from scientific teams across Singapore's research and innovation ecosystem. Working with these teams and their institutions, the Accelerator provides the portfolio, translational and commercial discipline required to identify and advance programmes with the greatest potential for therapeutic and commercial impact.
NATi is seeking a Portfolio Lead, Venture Creation & Commercialisation to serve as the senior commercial and venture-building leader within the Accelerator. Reporting to and working closely with the Head of Accelerator, the Portfolio Lead will be accountable for commercialisation strategy across the portfolio and the conversion of the strongest opportunities into investible, independently sustainable biotechnology companies, while advancing licensing, partnering and other commercial pathways where these offer greater value.
Position Summary
This is a hands-on venture-building and commercialisation role. The successful candidate will bring rigorous commercial and investment judgement to portfolio decisions, helping determine which programmes should be accelerated, continued, redirected, slowed, partnered/licensed or discontinued based on their technical differentiation, competitive position, commercial viability and investment potential.
For programmes selected for spin-off, the Portfolio Lead will drive the journey from promising science to a financeable and sustainable biotechnology company, including development of the venture thesis, investment proposition, company strategy, founding team, capital strategy, investor engagement and commercial aspects of company formation.
NATi's ambition is to deliver the first high-quality, investment-ready biotech spin-off from the Accelerator portfolio in 2027, followed by a second by mid-2028. From 2029, the objective is to establish a sustainable venture-creation flywheel capable of delivering at least one high-quality spin-off annually, alongside licensing, partnering and other commercial outcomes. Success will not be defined by incorporation alone, but by the creation of companies with differentiated and defensible assets, credible leadership, investor validation and a viable pathway to independent financing and long-term sustainability in Singapore. Company formation should be the consequence of investment readiness, not the measure of success.
Working closely with the Head of Accelerator, the Portfolio Lead will serve as the senior commercial and venture-creation thought partner, with clear accountability for commercialisation strategy, commercial and investment assessment, investment readiness, venture building, investor strategy and commercial execution.
Key Responsibilities
1. Lead Portfolio Commercialisation & Investment Strategy
- Develop and execute the commercialisation and venture-creation strategy across the Accelerator portfolio, aligned with the direction set by the Head of Accelerator.
- Work with Portfolio Domain Leads and programme teams to assess technical differentiation, IP/FTO, unmet need, competitive landscape, development risk, market opportunity and investment potential.
- Establish commercial stage gates and investment-readiness criteria, assessing opportunities against the anticipated future competitive landscape, not simply today's standard of care.
- Recommend which programmes should be accelerated, continued, redirected, partnered/licensed, deprioritised or discontinued, focusing resources on the most differentiated, investible and commercially compelling opportunities.
- Translate commercial and investment diligence into clear portfolio recommendations for NATi leadership and institutional stakeholders.
2. Drive Investment Readiness & Venture Creation
- Identify programmes with the strongest potential to support sustainable biotechnology companies and define the scientific, IP, commercial, leadership and financing gaps required to achieve investment readiness.
- Develop the venture thesis, commercial positioning, target product profile, company and pipeline strategy, investment proposition and value-creation plan with Domain Leads, programme teams and scientific founders.
- Translate investor, market and competitive insights into actionable evidence requirements that strengthen differentiation and investibility.
- Define company scope, development milestones, operating model, governance and capital requirements, and help secure credible founding leadership.
- Coordinate the commercial aspects of IP licensing, institutional arrangements, governance and company formation.
3. Lead Capital Formation & Investor Strategy
- Own financing strategies for proposed spin-offs, including capital requirements, use of proceeds, value-inflection milestones, financing rounds and investor strategy.
- Build relationships with specialist life-sciences VCs, strategic investors and other sources of biotechnology capital in Singapore and internationally.
- Engage investors before incorporation to pressure-test venture theses, identify evidence gaps and progressively build investment conviction.
- Develop investor narratives, financing materials and diligence packages, and lead investor engagement, syndicate development and financing execution with the Head of Accelerator and institutional stakeholders.
- Position each venture to secure credible third-party financing at formation and establish a pathway to subsequent independent financing.
4. Build the Future Venture Pipeline
- Proactively source high-potential nucleic acid therapeutics programmes from Singapore's research institutes, universities and hospitals to sustain at least one high-quality spin-off annually from 2029.
- Define venture-oriented investment theses and priority areas across indications, modalities and platform technologies, informed by investor, pharmaceutical partner and competitive insights.
- Work with the Head of Accelerator and Portfolio Domain Leads to establish selection criteria balancing scientific merit with differentiation, IP position, founder potential and investment readiness.
- Recommend project scope, funding allocation and milestone-based investment, working backwards from venture-creation and financing requirements.
- Manage portfolio depth and stage balance, accounting for expected attrition, while engaging inventors and technology-transfer offices early to establish appropriate IP protection and commercialisation pathways.
Qualifications & Experience
- Advanced degree in life sciences, medicine, engineering, business or a related discipline; PhD, MD and/or MBA qualifications are advantageous.
- 12+ years of relevant experience spanning biotechnology venture creation, life-sciences investing, venture capital, commercialisation, business development and/or biotechnology company building.
- Strong and attributable track record of translating early-stage therapeutic science into financed biotechnology companies, licensed assets, partnerships or strategic transactions.
- Strong ability to assess early-stage science through both a technical and investment lens, with sound judgement on when programmes should be accelerated, redirected, deprioritised or discontinued.
- Demonstrated experience attracting venture or strategic capital and developing financing strategies around scientific and development value-inflection points.
- Experience identifying, engaging or recruiting founders, entrepreneurs-in-residence and other senior biotechnology leaders.
- Experience in licensing, investment, collaboration, partnering or company-formation transactions, including working across multiple institutional stakeholders.
- Experience with RNA therapeutics, nucleic acid medicines, genetic medicines or other advanced therapeutic modalities would be particularly valuable.
- Experience commercialising science originating from universities, hospitals, research institutes or other public-sector research organisations, ideally in multi-institutional settings, is highly desirable.
- Established relationships across the venture capital, biotechnology and pharmaceutical communities in APAC and internationally are highly valued.
- Strong ability to lead through influence across institutional boundaries, align scientific, commercial and investment stakeholders, and operate effectively as a senior thought partner to the Head of Accelerator.
- Commercially rigorous, entrepreneurial and execution-oriented, with the judgement and resilience to build ventures from incomplete information while maintaining high standards of integrity and institutional stewardship